These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24027631)

  • 21. [Clinical and pathological characteristics of FUS/TLS-associated amyotrophic lateral sclerosis (ALS)].
    Murayama S
    Rinsho Shinkeigaku; 2010 Nov; 50(11):948-50. PubMed ID: 21921522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transportin1: a marker of FTLD-FUS.
    Brelstaff J; Lashley T; Holton JL; Lees AJ; Rossor MN; Bandopadhyay R; Revesz T
    Acta Neuropathol; 2011 Nov; 122(5):591-600. PubMed ID: 21847626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.
    Page T; Gitcho MA; Mosaheb S; Carter D; Chakraverty S; Perry RH; Bigio EH; Gearing M; Ferrer I; Goate AM; Cairns NJ; Thorpe JR
    J Mol Neurosci; 2011 Nov; 45(3):409-21. PubMed ID: 21603978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of glucose hypometabolism can help differentiate FTLD-FET from other types of FTLD.
    Garcia-Guaqueta DP; Ghayal NB; Lowe VJ; Dickson DW; Whitwell JL; Josephs KA
    J Neurol; 2024 Sep; 271(9):6264-6273. PubMed ID: 39088063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An autopsy case of neuronal intermediate filament inclusion disease with regard to immunophenotypic and topographical analysis of the neuronal inclusions.
    Inoue K; Fujimura H; Ueda K; Matsumura T; Itoh K; Sakoda S
    Neuropathology; 2015 Dec; 35(6):545-52. PubMed ID: 26096780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions.
    Mackenzie IR; Foti D; Woulfe J; Hurwitz TA
    Brain; 2008 May; 131(Pt 5):1282-93. PubMed ID: 18362096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Frontotemporal lobar degeneration (FTLD) - changes of its concept and classification based on aggregated proteins].
    Nakano I
    Rinsho Shinkeigaku; 2012; 52(11):1218-20. PubMed ID: 23196569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
    Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
    J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ubiquitin immunohistochemistry of frontotemporal lobar degeneration differentiates cases with and without motor neuron disease.
    Katsuse O; Dickson DW
    Alzheimer Dis Assoc Disord; 2005; 19 Suppl 1():S37-43. PubMed ID: 16317257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined fused in sarcoma-positive (FUS+) basophilic inclusion body disease and atypical tauopathy presenting with an amyotrophic lateral sclerosis/motor neurone disease (ALS/MND)-plus phenotype.
    Wharton SB; Verber NS; Wagner BE; Highley JR; Fillingham DJ; Waller R; Strand K; Ince PG; Shaw PJ
    Neuropathol Appl Neurobiol; 2019 Oct; 45(6):586-596. PubMed ID: 30659642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation.
    Mackenzie IR; Ansorge O; Strong M; Bilbao J; Zinman L; Ang LC; Baker M; Stewart H; Eisen A; Rademakers R; Neumann M
    Acta Neuropathol; 2011 Jul; 122(1):87-98. PubMed ID: 21604077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
    Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
    Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
    Neumann M
    Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation.
    Suzuki N; Kato S; Kato M; Warita H; Mizuno H; Kato M; Shimakura N; Akiyama H; Kobayashi Z; Konno H; Aoki M
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):779-88. PubMed ID: 22878663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis.
    Deng HX; Zhai H; Bigio EH; Yan J; Fecto F; Ajroud K; Mishra M; Ajroud-Driss S; Heller S; Sufit R; Siddique N; Mugnaini E; Siddique T
    Ann Neurol; 2010 Jun; 67(6):739-48. PubMed ID: 20517935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
    A Armstrong R
    Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
    Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
    Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.